Ann: Anteo Presents at Largest IVD Trade Show in China, page-42

First 42 Last

Share
Profile

Follow
muppet655

3,740 Posts.

106

15/03/17

10:18

Post #: 23355543
Share

Originally posted by Twinvest ↑

Jak reality is 50% of investments don't work out.

This can have to do with the company itself but usually the biggest factor is the individual investor - how and when they buy and sell.

The biggest failure for Anteo in the time I have been invested is not the lack of revenue generating contracts but the blatant breach of disclosure with regards to share lending / loan agreements.

The strategy to buy Disource was actually good - how it was financed was not.

This is what caused the immediate sell down following the Disource announcement - nothing else.

So while no steps have been taken yet it is interesting to look at what has potentially happened with links to inside information and company strategies etc that all investors are not privy to. So how someone can say at a public agm that what the shareholder does with their trading behind closed doors is their business when they themselves have an interest in that shareholders company and are feeding them daily inside information. This is the biggest reason Anteo has failed post diasource - Bergen was just a secondary that compounded the supply.

No interest in buy side demand is simple - why would you until you see what their plan is to sort earnout.

Wonder how much money was made on this naked short they executed so confidently?

Board still needs sorting but next agm should take care of that.

Expand

I have to agree with Hangas, the company has failed time and again with it core offering being dismally rejected as a commercial prospect this far. Lots of interest and toying with it but no one willing to pay for it thus far.

ADO Price at posting: 3.4¢ Sentiment: None Disclosure: Not Held
7 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 139 more messages in this thread...

First 42 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.001(4.76%)		Mkt cap ! $54.77M

Open	High	Low	Value	Volume
2.1¢	2.2¢	2.1¢	$21.58K	1.020M

Buyers (Bids)

No.	Vol.	Price($)
1	100000	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	378168	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.021
10	1443457	0.020
10	2127381	0.019
5	1657002	0.018
4	1574748	0.017

Price($)	Vol.	No.
0.022	378168	5
0.023	642868	9
0.024	141966	2
0.025	478846	7
0.026	83915	2

Last trade - 16.10pm 07/10/2024 (20 minute delay)

ADO (ASX) Chart

Ann: Anteo Presents at Largest IVD Trade Show in China, page-42

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Anteo Presents at Largest IVD Trade Show in China, page-42

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News